Medolife Rx Starts Distribution of Its Products in Canada
BURBANK, CA / ACCESSWIRE / February 2, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that it began major distribution of its Quanta Muscle Rub™ products in Canada in collaboration with Better Health Sciences, Inc. During a pilot sale campaign, Better Health Sciences received exceptionally positive feedback from its customers on the Quanta Muscle Rub™, a topical product containing polarized CBD. In the first year, both companies project sales of over $1 million.
"The collaboration with Better Health Sciences, Inc. has two significant benefits for Medolife's presence in Canada" said CEO of Medolife, Dr. Arthur Mikaelian. "First, we will begin distributing larger quantities of Quanta Muscle Rub™ in Canada. Second, we will be licensing MRT-06 polarization machines, which apply electromagnetic frequencies to compounds, such as CBD, to enhance their quality and effectiveness."
Growing CBD Market
CBD-infused topicals provide various therapeutic benefits that appeal consumers: pain relief, inflammation reduction, and easing of skin issues. New scientific discoveries point to CBD for treatment of dry skin, psoriasis, and eczema. According to a 2019 report, published by Grant View Research, Inc., the global CBD market is expected to reach $23.6 billion by 2025. The demand for North American CBD topicals is expected to remain high, largely due to growing demand and legalization of cannabis in certain States in the U.S. and Canada.
"Better Health Sciences, Inc. intends to bring Medolife production and patented Mikaelian Resonance Technology polarization machines to Canada, allowing for a wider range of polarized products to be produced and available in the Canadian market," said Ilya Strashun, Co-Founder of Better Health Sciences, Inc. "Our target markets include national and major league sports teams, rehabilitation centers, wellness centers, clinics, and medium-large retailers."
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at http://medolife.com/.
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at https://buyquanta.com/.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
SOURCE: Quanta, Inc.
View source version on accesswire.com:
Released February 2, 2021